tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Fosun Pharma’s Subsidiary Drug Application Accepted by Chinese Authorities

Story Highlights
  • Fosun Pharma’s subsidiary’s drug application for Vincristine Sulfate Injection was accepted.
  • The drug targets several cancers, marking a key R&D milestone for Fosun Pharma.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Fosun Pharma’s Subsidiary Drug Application Accepted by Chinese Authorities

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).

Shanghai Fosun Pharmaceutical announced that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has had its drug registration application for Vincristine Sulfate Injection accepted by the National Medical Products Administration. This drug, developed independently by the company, is intended for the treatment of various cancers, including acute leukemia and Hodgkin lymphoma. The acceptance marks a significant step in the company’s R&D efforts, having invested approximately RMB3.03 million in the drug’s development, potentially enhancing its position in the oncology market.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceutical products, with a market emphasis on innovative drugs and healthcare services.

Average Trading Volume: 10,877,098

Technical Sentiment Signal: Hold

Current Market Cap: HK$79.26B

Learn more about 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1